> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Indivior Pays $300 Million in Suboxone Marketing Case
- URL: https://www.fdaweb.com/indivior-pays-300-million-in-suboxone-marketing-case/
- Published: 2021-05-14T12:00:00.000Z
- Updated: 2026-09-14T16:58:56.000Z
- Author: David McFarland
- Tags: Drugs, FDA Policy/General, #legacy-id-D5149328

Idaho attorney general **Lawrence Wasden** has [announced](https://www.ag.idaho.gov/newsroom/attorney-general-announces-idahos-participation-in-300-million-settlement-with-drugmaker-indivior/?ref=fdaweb.com) that an agreement was reached between all 50 states and Indivior that requires it to pay $300 million to settle allegations that the company falsely and aggressively marketed/promoted Suboxone (buprenorphine), which resulted in improper Medicaid expenditures.

Last year, Indivior pleaded guilty to one felony count and agreed to pay a total of $600 million to resolve criminal and civil liability associated with Suboxone’s marketing. An earlier $1.4 billion resolution with Indivior’s former parent, Reckitt Benckiser Group, and a plea agreement with Indivior former CEO, **Shaun Thaxter**, brings the total resolution to more than $2 billion — the largest settlement involving an opioid drug, according to a Justice Department [release](https://www.justice.gov/opa/pr/indivior-solutions-pleads-guilty-felony-charge-and-indivior-entities-agree-pay-600-million?ref=fdaweb.com).

Suboxone is a drug product approved for use by recovering opioid addicts to avoid or reduce withdrawal symptoms.